Researchers at University of California San Diego School of Medicine found that a diet low in free sugars (those added to foods and beverages and occurring naturally in fruit juices) resulted in significant improvement in nonalcoholic fatty liver disease (NAFLD) in adolescent boys.
A randomized clinical study of adolescent boys with nonalcoholic fatty liver disease (NAFLD) found that a diet low in free sugars (those sugars added to foods and beverages and occurring naturally in fruit juices) resulted in significant improvement in NAFLD compared to a usual diet.
The proportion of liver transplants in the United States for alcohol-associated liver disease increased between 2002 and 2016, with much of the increase associated with a decrease in liver transplant for hepatitis C virus infection because of antiviral therapy. This observational study used data from the United Network for Organ Sharing for all liver transplants during the 15-year period and the national study group consisted of nearly 33,000 patients, including 9,438 patients with a diagnosis of alcohol-associated liver disease.
The proportion of US liver transplants for alcohol-associated liver disease (ALD) has doubled in the last 15 years, in part due to broader acceptance of waiving the mandated period of sobriety before transplants for this population, according to a study by researchers at UC San Francisco, which showed ongoing regional geographic variations in liver transplant rates for ALD patients, whose long-term survival rate is slightly lower than other liver transplant patients. The study appears Jan. 22, 2019, in JAMA Internal Medicine.
Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Science Translational Medicine of clinical data from its Phase 1 clinical study in healthy volunteers and supporting preclinical data from its investigational Synthetic Biotic candidate, SYNB1020. The data support the continued development of SYNB1020 which is currently being evaluated in a Phase 1b/2a clinical trial in patients with cirrhosis and elevated blood ammonia.
Older mice who are surgically joined with young mice in order to share a common bloodstream get stronger and healthier, making parabiosis one of the hottest topics in age research. Publishing in Nature Metabolism, researchers report that MANF (mesencephalic astrocyte-derived neurotrophic factor) is one of the factors responsible for rejuvenating the transfused older mice. Researchers also show the naturally occurring, evolutionarily conserved repair mechanism protects against liver damage in aging mice and extends lifespan in flies.
Salk researchers have developed a new system that lets them study in more detail than ever exactly how, where and when the metabolic protein AMPK carries out its molecular and therapeutic functions.
In a paper to be published in the September/December 2019 issue of TECHNOLOGY, a team of researchers from the IIT, Chicago, has developed a novel microfluidic device for measuring in real-time the cholesterol secreted from liver tissue-chip containing human hepatocytes. This innovation can help researchers employing microfluidic cultures to study the effects of drugs such as statins on lowering cholesterol in real-time.
Most patients with ulcerative colitis (UC) have mild-to-moderate disease characterized by periods of activity or remission, but practice variations exist in disease management. A new clinical guideline from the American Gastroenterological Association (AGA) published in Gastroenterology, the official journal of AGA, addresses the medical management of these patients, focusing on use of both oral and topical 5-aminosalicylates (5-ASA) medications, rectal corticosteroids and oral budesonide, to promote high-quality care for UC patients.
Catheters are used today to deliver drugs directly to tumors to avoid broadcasting toxic chemotherapy agents throughout the body. Nevertheless, half of the drug can escape to the rest of the body, causing side effects. UC San Francisco doctors treating liver cancer teamed up with UC Berkeley chemical engineers to design a polymer-coated device that can be temporarily placed in the vein coming out of the liver to absorb unused drugs, potentially lowering risk.